Color Health, a genetic testing company, is using the latest, lower-cost, multilingual OpenAI model to equip physicians with treatment readiness expertise that can speed up advance authorization applications for cancer screening and get patients on treatment more quickly.
The company also partnered with the University of California, San Francisco to study how the Cancer Co-Pilot tool does in detecting early warning signs, seemingly inappropriate red flags and other vital details that can be deeply scattered throughout electronic health records and other patient information .
WHY IT IS IMPORTANT
Although decision-making factors vary for different types of cancer, the company says testing of the technology has allowed providers to analyze patient records within five minutes.
“Primary care physicians typically do not have the time, or sometimes even the expertise, to adapt screening guidelines to risk,” said Othman Laraki, co-founder and CEO of Color Health. report Monday.
The Helen Diller Family Comprehensive Cancer Center at the University of California, Los Angeles is testing the Color second pilot for pre-treatment cancer diagnosis, comparing it with retrospective chart reviews of cancer patients.
Although this study is in its early stages, according to a Color Color spokesperson, if artificial intelligence can ultimately reduce wait times for cancer treatment by connecting the dots, it will be a victory in patient care.
In color announcement On Monday, Laraki said the company designed the tool to fill a gap in the supply of expertise in oncology and inform testing decisions before treating a patient with a confirmed malignancy.
The goal is to offer primary care physicians and other clinicians an artificial intelligence service that can determine what tests are needed to inform a patient about cancer treatment, without waiting for the patient to see an oncologist before ordering pre-treatment diagnostics and starting the prior authorization process, he explained.
“This way, by the time a patient first meets with her oncologist, she has a much better chance of being ready to start treatment and hopefully saving weeks of valuable time.”
Laraki also emphasized the clinician’s role in decision-making when using this tool.
“One of the most important design decisions we made during our work was to build tools from scratch based on a human-in-the-loop model,” he said.
The company said it will share the results of the first tested employ case – which focuses on automating the analysis of an individual’s risk factors and then applying guidelines to adapt the screening plan – first to people in the cancer program and then to primary care providers. doctors a chance to check the information.
Color estimated that by the end of the year, physicians using Cancer Treatment Co-Pilot will support more than 200,000 patient cases in creating personalized, AI-powered care plans.
A BIGGER TREND
Before Color focused on tools to support doctors improve outcomes for cancer patients, it launched a patient-initiated proactive testing model in 2015. The tests focused on genes known to boost a person’s risk of developing cancer, such as BRCA1 and BRCA2 for breast, ovarian and pancreatic cancers. .
Within a few years unicornalong with 23andMe and other companies, it has broken down barriers for patients that previously hindered cancer screening by offering affordable, over-the-counter home test kits that can highlight key genetic risk factors.
The employ of artificial intelligence in a fresh decision support service that enables PCPs to initiate treatment for cancer patients more quickly is a growing area of artificial intelligence in healthcare, where automating physician note-taking and reducing administrative burdens are most of the main applications of the LLM.
However, applying machine learning to health data represents a major opportunity to improve health outcomes for individuals and populations.
Artificial intelligence can play a key role in disease management, said Xin Wang, an assistant professor in the department of epidemiology and biostatistics at the University at Albany.
“By analyzing patient data over time, AI algorithms can predict individual patient risk, suggest personalized treatment plans, and even alert healthcare providers to early signs of complications,” he said in January.
“This proactive approach can lead to earlier interventions, better disease management and ultimately better health outcomes.”
ON RECORDING
“We see a perfect fit between AI technology and language models,” Brad Lightcap, OpenAI’s chief operating officer, said in the article. “They can give physicians more tools to understand medical records, understand data, understand labs and diagnostics.”